These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome.
    Author: Zhao L, Yao L, Yuan L, Xia L, Shen H, Lu J.
    Journal: Cytokine; 2013 Oct; 64(1):22-4. PubMed ID: 23910012.
    Abstract:
    OBJECTIVE: To determine whether interleukin (IL)-33 and soluble ST2 (sST2) are associated with primary Sjogren's Syndrome (pSS). METHODS: Serum levels of IL-33 and sST2 in 110 pSS patients and 78 healthy controls were measured by enzyme-linked immunosorbent assay (ELISA). Immunoglobulins, rheumatoid factors (RF), antinuclear antibody (ANA), anti-SSA/RO-52 antibody, anti-SSB antibody and erythrocyte sedimentation rate (ESR) were measured by standard laboratory techniques. Interstitial lung disease (ILD) was identified on high-resolution computed tomography (HRCT). Disease activity in pSS was scored with the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI). RESULTS: Serum levels of IL-33 and sST2 were significantly elevated in pSS patients, especially in patients with ILD. There was significant positive correlation between IL-33 and RF, anti-SSB antibody. CONCLUSION: IL-33/sST2 may be involved in the pathogenesis of pSS and partly contribute to the ILD in pSS patients.
    [Abstract] [Full Text] [Related] [New Search]